NASDAQ:ENSC Ensysce Biosciences Q3 2025 Earnings Report $0.35 -0.03 (-8.12%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ensysce Biosciences EPS ResultsActual EPS-$1.29Consensus EPS -$0.85Beat/MissMissed by -$0.44One Year Ago EPSN/AEnsysce Biosciences Revenue ResultsActual Revenue$0.49 millionExpected Revenue$0.70 millionBeat/MissMissed by -$206.90 thousandYoY Revenue GrowthN/AEnsysce Biosciences Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time4:00PM ETUpcoming EarningsEnsysce Biosciences' Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Ensysce Biosciences Earnings HeadlinesEnsysce Biosciences (ENSC) Expected to Announce Earnings on TuesdayMay 10 at 3:34 AM | americanbankingnews.comENSC Making Great Strides Toward CommercializationMarch 31, 2026 | msn.comBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says 'The Final Phase of Elon's Master Plan' is about to trigger one of the biggest wealth transfers in market history. He's identified one ticker positioned to capture it - and it isn't SpaceX or Tesla. He's releasing the name for free, but the window is closing.May 12 at 1:00 AM | Brownstone Research (Ad)Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic ReviewFebruary 27, 2026 | benzinga.comENSC expands its global patent portfolioJanuary 21, 2026 | msn.comEnsysce Biosciences Shareholders Approve Key Corporate ActionsJanuary 10, 2026 | theglobeandmail.comSee More Ensysce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email. Email Address About Ensysce BiosciencesEnsysce Biosciences (NASDAQ:ENSC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features. The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations. Ensysce is advancing ENS100 through preclinical studies and regulatory interactions, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Beyond pain management, the platform underpins additional pipeline programs targeting other central nervous system indications where controlled drug delivery may enhance therapeutic benefit and safety. Founded with a mission to address critical public health challenges, Ensysce Biosciences operates primarily in the United States and engages in collaborative partnerships to support its research and development activities. The company holds a portfolio of issued patents and pending applications covering its enzyme-activated prodrug technologies, reflecting a commitment to innovation in the design of safer pharmaceutical therapies.View Ensysce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingMP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
